2772-6134

Clinical Immunology Communications

Elsevier

View prefix report (10.1016)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 141 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact141 DOIs
2

Attach ORCID iDs across 31 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact31 DOIs
3

Deposit reference lists for 10 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact10 DOIs

DOIs for this ISSN

Showing the top 5 of 141 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Aptamer: A theranostic approach towards breast cancer (10.1016/j.clicom.2023.06.002)
Abstract ORCID
62.76 17
2 Identification and functional analysis of exosomal miR-16-5p… (10.1016/j.clicom.2022.08.002)
Abstract ORCID
57.31 13
3 Daily oral vitamin D3 without concomitant therapy in the man… (10.1016/j.clicom.2022.01.001)
Abstract ORCID
55.70 12
4 Beneficial immune-regulatory effects of novel strains of Aur… (10.1016/j.clicom.2021.11.001)
Abstract ORCID
53.96 11
5 Pfizer–biontech COVID-19 RNA vaccination induces phosphatidy… (10.1016/j.clicom.2021.08.001)
Abstract ORCID
50.00 9
6 Trained innate immunity and diseases: Bane with the boon (10.1016/j.clicom.2022.08.004)
Abstract ORCID
50.00 9
7 Guillain-Barre syndrome: An autoimmune disorder post-COVID-1… (10.1016/j.clicom.2021.12.002)
Abstract ORCID
47.71 8
8 Real-life efficacy and safety of mepolizumab for eosinophili… (10.1016/j.clicom.2022.01.002)
Abstract ORCID
47.71 8
9 Altered pre-existing SARS-CoV-2-specific T cell responses in… (10.1016/j.clicom.2021.12.001)
Abstract ORCID
45.15 7
10 Inhibiting VEGF in cancer immunotherapy (10.1016/j.clicom.2021.12.003)
Abstract ORCID
38.91 5
11 Nasalferon, a new nasal formulation of IFNα2b, modulates cel… (10.1016/j.clicom.2022.02.002)
Abstract ORCID
38.91 5
12 The “original antigenic sin” and its relevance for SARS-CoV-… (10.1016/j.clicom.2021.10.001)
Abstract
36.56 28
13 Post COVID-19 multisystem inflammatory syndrome in adults (M… (10.1016/j.clicom.2024.04.003)
Abstract ORCID
34.95 4
14 The impact of diet on gut microbiome composition: Implicatio… (10.1016/j.clicom.2025.12.001)
Abstract
28.65 13
15 C1 esterase inhibitor-mediated immunosuppression in COVID-19… (10.1016/j.clicom.2022.05.001)
Abstract
26.03 10
16 Covid-19 Vaccine safety and adverse event analysis from Paki… (10.1016/j.clicom.2022.05.003)
Abstract
26.03 10
17 Successful desensitization in a patient with adalimumab hype… (10.1016/j.clicom.2022.01.003)
Abstract ORCID
23.86 2
18 Potential role of uric acid to activate NLRP3 inflammasome t… (10.1016/j.clicom.2022.03.003)
Abstract
23.86 8
19 Lower NK cell numbers in children with untreated juvenile de… (10.1016/j.clicom.2023.02.007)
Abstract
23.86 8
20 Novel approaches that promote lung endothelial and epithelia… (10.1016/j.clicom.2023.07.005)
Abstract ORCID
23.86 2
21 Challenges in the diagnosis and management of SLE in India (10.1016/j.clicom.2023.10.001)
Abstract
23.86 8
22 Systemic lupus erythematosus in Latin America: Outcomes and… (10.1016/j.clicom.2023.10.002)
Abstract
23.86 8
23 Functional thermostable postbiotic derivatives from Lactobac… (10.1016/j.clicom.2025.10.001)
Abstract ORCID
23.86 2
24 Reduced immune system responsiveness in fibromyalgia - A pil… (10.1016/j.clicom.2022.02.003)
Abstract
22.58 7
25 Nailfold capillary dropout precedes the presentation of pneu… (10.1016/j.clicom.2023.06.001)
Abstract
22.58 7
26 GROWTH HORMONE, IMMUNOSENESCENCE AND VACCINATION FAILURE IN… (10.1016/j.clicom.2023.02.005)
Abstract
21.13 6
27 Serum calprotectin is useful to confirm inflammatory bowel d… (10.1016/j.clicom.2022.02.001)
Abstract
19.45 5
28 Myocarditis following Coronavirus vaccination (10.1016/j.clicom.2022.11.001)
Abstract
19.45 5
29 IL-23 Inhibitors to treat psoriatic arthritis: A systematic… (10.1016/j.clicom.2023.07.001)
Abstract
19.45 5
30 Efficacy and safety of current treatments for paroxysmal noc… (10.1016/j.clicom.2022.11.002)
Abstract
17.47 4
31 Differential peripheral blood mononuclear cell reactivity ag… (10.1016/j.clicom.2022.11.004)
Abstract
17.47 4
32 X-Linked Inhibitor of Apoptosis (XIAP) deficiency presenting… (10.1016/j.clicom.2023.02.008)
Abstract
17.47 4
33 Early recognition of the APECED rash can accelerate the diag… (10.1016/j.clicom.2024.03.001)
Abstract
17.47 4
34 Role of skin antimicrobial peptides in the pathogenesis of p… (10.1016/j.clicom.2024.12.001)
Abstract
17.47 4
35 Involvement of β-glucan receptors on the antitumor activity… (10.1016/j.clicom.2024.12.002)
Abstract
17.47 4
36 Systems immunology meets clinical translation: Multi-omic ap… (10.1016/j.clicom.2025.12.002)
Abstract
17.47 4
37 COVID-19 in a patient with Good's syndrome and in 13 patient… (10.1016/j.clicom.2021.08.003)
Abstract
15.05 3
38 Protective role of human beta-defensin-2 and cathelicidin in… (10.1016/j.clicom.2023.02.006)
Abstract
15.05 3
39 B cell depletion in infants after intra uterine exposure to… (10.1016/j.clicom.2023.06.004)
Abstract ORCID
15.05 1
40 Immune microenvironment and progress in immunotherapy of cho… (10.1016/j.clicom.2023.11.002)
Abstract ORCID
15.05 1
41 First reported use of immune checkpoint inhibitor for treatm… (10.1016/j.clicom.2024.04.001)
Abstract
15.05 3
42 Immunologic profiles and infection patterns in patients with… (10.1016/j.clicom.2025.09.001)
Abstract
15.05 3
43 Prevalence of asymptomatic SARS-CoV-2 infection in an Austri… (10.1016/j.clicom.2021.08.002)
Abstract
11.93 2
44 Pharmacokinetics of convalescent plasma therapy in a COVID-1… (10.1016/j.clicom.2022.03.001)
Abstract
11.93 2
45 Appraising SARS-CoV-2 infections after full mRNA COVID-19 va… (10.1016/j.clicom.2022.03.002)
Abstract
11.93 2
46 Meningoradiculitis post-COVID-19 mRNA vaccination: A case re… (10.1016/j.clicom.2022.03.004)
Abstract
11.93 2
47 Hepatitis E virus sero-prevalence among pregnant women in Kh… (10.1016/j.clicom.2022.04.001)
Abstract
11.93 2
48 Endogenous antibody response to SARS-CoV-2 in patients who r… (10.1016/j.clicom.2022.08.003)
Abstract
11.93 2
49 Memory T cell responses in seronegative older adults followi… (10.1016/j.clicom.2022.09.005)
Abstract
11.93 2
50 High neutrophil/lymphocyte ratio and low lymphocyte percenta… (10.1016/j.clicom.2022.11.003)
Abstract
11.93 2